Gold mining stocks are hot right now. Economic uncertainty, inflation fears and the prospects of a tariff war are making a lot of investors look to traditional flight-to-safety stocks, and gold miners are a classic choice. But precious metals don't begin or endI’m Jason Ditz and I have 20 years of experience in foreign policy research. My work has appeared in Forbes, Toronto Star, Minneapolis Star-Tribune, Providence Journal, Washington Times and the Detroit Free Press, as well as American Conservative Maga ...

Core Viewpoint - Five Below, Inc. (FIVE) has raised its sales and earnings outlook for Q1 fiscal 2025, leading to an 11.9% increase in stock price, driven by strong performance and a leadership transition that signals confidence in long-term strategy [1][4][7]. Financial Outlook - The company expects net sales for Q1 fiscal 2025 to reach $967 million, up from previous guidance of $905-$925 million, compared to $811.9 million in Q1 fiscal 2024 [4]. - Projected store openings for the quarter are now 55, exceeding the earlier estimate of 50 [5]. - Comparable sales are anticipated to rise by 6.7%, a significant improvement from the earlier projection of flat to modest 2% growth [5]. - Earnings per share are forecasted between 69 cents and 71 cents, an increase from the previous estimate of 44-55 cents, with adjusted earnings expected to be 82-84 cents compared to the prior estimate of 50-61 cents [6]. Leadership Transition - Tom Vellios, co-founder and executive chair, will step down from the board after the 2025 annual meeting, transitioning to an advisory role [7]. - Mike Devine, a current board member, is expected to be appointed as non-executive chair, bringing extensive governance experience [8]. Company Strategy and Market Position - Five Below has positioned itself as a leading destination for pre-teens and teens, focusing on trendy, high-quality products at exceptional value [9]. - The company has realigned its strategy to emphasize product, value, and customer experience, which has gained momentum since Q3 fiscal 2024 [10]. - Despite ongoing challenges such as rising costs and a competitive retail landscape, Five Below remains committed to its growth strategy [10][11].

Group 1 - Exelon Corporation (NASDAQ: EXC) was previously identified as a buy due to its superior performance compared to other utilities across various metrics [1] - The analysis emphasizes the company's potential for value return to investors, highlighting its underappreciated status in the market [1] Group 2 - The author has extensive experience in investment analysis, focusing on deep-discount value plays and contrarian investment philosophy [1]

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or ...

Core Insights - Phathom Pharmaceuticals is set to present real-world data on its first-in-class treatment VOQUEZNA (vonoprazan) for gastroesophageal reflux disease (GERD) at Digestive Disease Week (DDW) from May 3-6, 2025, in San Diego, CA [1][3] - VOQUEZNA is the only treatment approved by the U.S. FDA for adults for heartburn relief associated with Non-Erosive GERD and for treating all severities of Erosive Esophagitis (Erosive GERD) [1][34] - The data presented will analyze treatment patterns and patient characteristics, indicating VOQUEZNA's potential role for patients inadequately managed by existing therapies [3] Company Activities - Two Phathom-sponsored posters will be presented on May 5, 2025, at the conference, along with a Product Theater highlighting VOQUEZNA [2] - The company will maintain a strong presence at the conference with a booth (1743) on the exhibit floor [2] Industry Context - GERD affects approximately 1 in 5 U.S. adults, with around 70% of the GERD population suffering from Non-Erosive GERD [31][32] - Erosive GERD, affecting about 30% of the GERD population, can lead to severe complications if inadequately treated [33] - The conference will showcase over 5,600 abstracts and hundreds of lectures on the latest advances in GI research, medicine, and technology [8]

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Q4 2024 Earnings Conference Call March 6, 2025 8:30 AM ET Company Participants Eric Sciorilli - Head, Investor Relations Terrie Curran - President & Chief Executive Officer Martin Gilligan - Chief Commercial Officer Molly Henderson - Chief Financial Officer Conference Call Participants Yatin Suneja - Guggenheim Joseph Stringer - Needham Annabel Samimy - Stifel Kristen Kluska - Cantor Fitzgerald Paul Choi - Goldman Sachs Matthew Caufield - H.C. Wainwright Operator ...